Andere Sprachen Clene Inc.

Aktien

A2QE9Y

US1856341029

CLNN

Verzögert Nasdaq Andere Börsenplätze 17:41:37 25.04.2024			% 5 Tage	% 1. Jan.
0.3401 ^USD	+0.91%		+3.09%	+14.67%

16.04.	Clene Inc. und Clene Nanomedicine, Inc. präsentierten die Ergebnisse der Phase-2-Studie VISIONARY-MS Long term Extension (LTE) auf der Jahrestagung 2024 der American Academy of Neurology (AAN) in Denver	CI
15.03.	Clene Inc. gibt eine von Experten begutachtete Veröffentlichung zur Charakterisierung der Proteinkorona des Wirkstoffs CNM-Au8 bekannt, der für neurodegenerative Erkrankungen erforscht wird	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Clene : 2023 Annual Report to Stockholders	17.04.
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting	16.04.
Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	16.04.
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington	19.03.
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®	15.03.
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	15.03.
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights	13.03.
Clene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13.03.
North American Morning Briefing : Stock Futures -2-	11.03.
Clene to Present at the 36th Annual ROTH Conference	07.03.
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024	29.02.
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs	22.02.
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs	22.02.
Clene Inc. announces positive results from CNM-Au8 results from MS trial	05.02.
Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension	08.01.
Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial	08.01.
US FDA finds Clene's trial data for ALS drug to be insufficient	21.12.
Clene Provides Update on ALS Clinical Development Meeting With FDA	21.12.
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension	21.12.
Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases	14.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Clene Inc.

Aktien

A2QE9Y

US1856341029

CLNN

Andere Sprachen

Filter